XBIO:NASDAQ, Xenetic Biosciences, Inc.

Why XBIO stock fell on November 12

Xenetic Biosciences, Inc. fell 11.0% on Thursday, November 12, 2026, on 22,000 shares. The headline around the move:

XBIO stock overview

Xenetic Biosciences, Inc. (XBIO:NASDAQ) closed at $1.49 on November 16, 2026, down 10.24% on the day. The stock trades 69.8% below its 52-week high of $4.94 and 4.2% above its 52-week low of $1.43. Over the past year, it lost 40.2%. Xenetic Biosciences, Inc. is part of the Health Care sector (Major Pharmaceuticals).

Key figures

Price
$1.49
Day change
-10.24%
Volume
17,504
Average volume
74,131
Market cap
3M+
52-week range
$1.43 – $4.94
50-day average
$2.42
200-day average
$2.81

Price action over the past year

In 252 trading sessions since November 14, 2025, XBIO closed higher on 119 days (47%). Its best day was March 16, 2026 (+20.37%) and its worst was September 16, 2026 (-48.71%). The stock moved 10% or more in a single session 15 times. It opened at least 5% above the previous day's high 3 times.

Recent signals

XBIO news

About Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and planned commercialization of human drug therapies for the treatment of various conditions. Its drug delivery platform systems include PolyXen for creating next generation biologic drugs; OncoHist for the development of oncology drugs focused on orphan indications; Virexxa for the treatment of progesterone receptor negative endometrial cancer; and ImuXen for the development of vaccines that can simultaneously deliver multiple active pharmaceutical ingredients. Its product candidates comprise ErepoXen, a polysialylated erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease; and OncoHist, an orphan drug that is in pre-clinical stage of development for the treatment of refractory acute myeloid leukemia. The company is also developing a pipeline of drug candidates for next generation biologics and novel oncology therapeutics in various orphan disease indications. It has a research, development, license, and supply agreement with Baxter Healthcare SA and Baxter Healthcare Corporation for Factor VIII to treat hemophilia; a collaborative...

Similar stocks

Find more stocks like XBIO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.